CN112370483A - 一种治疗脂肪肝的中药组合物 - Google Patents
一种治疗脂肪肝的中药组合物 Download PDFInfo
- Publication number
- CN112370483A CN112370483A CN202011563670.6A CN202011563670A CN112370483A CN 112370483 A CN112370483 A CN 112370483A CN 202011563670 A CN202011563670 A CN 202011563670A CN 112370483 A CN112370483 A CN 112370483A
- Authority
- CN
- China
- Prior art keywords
- parts
- fatty liver
- traditional chinese
- chinese medicine
- treating fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 21
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 20
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 20
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims description 11
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 8
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 8
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 7
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 6
- 244000235603 Acacia catechu Species 0.000 claims abstract description 6
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 6
- 241001061264 Astragalus Species 0.000 claims abstract description 6
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims abstract description 6
- 235000008671 Calycanthus floridus Nutrition 0.000 claims abstract description 6
- 235000008670 Calycanthus occidentalis Nutrition 0.000 claims abstract description 6
- 244000148992 Lindera benzoin Species 0.000 claims abstract description 6
- 235000004520 Lindera benzoin Nutrition 0.000 claims abstract description 6
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 claims abstract description 6
- 241001608711 Melo Species 0.000 claims abstract description 6
- 235000006533 astragalus Nutrition 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗脂肪肝的中药，是由下列重量份的原料药组成：瓜蒂0.5～1重量份；儿茶1.5～3重量份；穿山龙、余甘子、乌药4～8重量份；沙苑子、地骨皮9～18重量份；绞股蓝15～30重量份。
Description
技术领域
本发明属于中药技术领域，尤其是涉及一种治疗脂肪肝的中药。
背景技术
脂肪肝，是指由于各种原因引起的肝细胞内脂肪堆积过多的病变。脂肪性肝病正严重威胁国人的健康，成为仅次于病毒性肝炎的第二大肝病，已被公认为隐蔽性肝硬化的常见原因。目前，没有治疗脂肪肝的特效药。
发明内容
本发明的目的在于改进已有技术的不足而提供一种治疗脂肪肝的中药组合物，可以有效地改善甚至消除患者的临床症状，具有治疗效果显著、治疗周期短、无毒副作用等特点。
本发明提供了一种治疗脂肪肝的中药，由下列重量份的原料药组成：瓜蒂0.5～1重量份；儿茶1.5～3重量份；穿山龙、余甘子、乌药4～8重量份；沙苑子、地骨皮9～18重量份；绞股蓝15～30重量份。
在一个优选的实施方案中，所述治疗脂肪肝的中药组合物由下列重量份的原料药组成：瓜蒂1重量份；儿茶3重量份；穿山龙、余甘子、乌药8重量份；沙苑子、地骨皮18重量份；绞股蓝30重量份。
其中,绞股蓝：味苦；微甘；性凉。归肺；脾；肾经。清热；补虚；解毒。绞股蓝对人体内脂肪有良性转化调节作用。绞股蓝能抑制脂肪细胞产生游离脂肪酸及合成中性脂肪。绞股蓝总皂甙具有广泛的抗氧化效果，可保护生物膜免受氧化损伤，能明显降低肝脏LPO含量,明显对抗血清总胆固醇升高，不仅能提高肝脏SOD活力，同时也增强了SOD耐热、耐酸性能，起了保护SOD的作用。
沙苑子：甘，温。归肝、肾经。温补肝肾，固精，缩尿，明目。明显降低胆固醇和甘油三酯，降低低密度脂蛋白，显著降低肝中固醇含量，显著减轻肝脂肪变。
儿茶：苦、涩，微寒。归肺经。收湿生肌敛疮，保肝、利胆。所含d-儿茶精及表儿茶精均有显著保肝作用，对肝脂肪变有明显保护效果。
瓜蒂：苦，寒。有毒。催吐，退黄疸。瓜蒂明显降低血清丙氨酸转氨酶，能明显抑制肝纤维组织增生，有效治疗肝脂肪变性以及肝硬变，促使损伤的肝细胞修复，肝功能恢复正常。
地骨皮：甘，寒。归肺、肝、肾经。凉血除蒸，清肺降火。地骨皮能显著降低血清总胆固醇含量，有抗脂肪肝作用。
穿山龙：苦，平。舒筋活络，祛风止痛。穿山龙能显著降低血胆甾醇，减轻主动脉斑块、肝脏脂肪沉积。
余甘子：甘、酸、涩、凉。归肺、胃经。余甘子是一种很好的天然降脂药物，可明显抑制主动脉内膜斑块的形成，能加速胆固醇及磷脂从粪便中排泄，明显降低胆固醇、脂质体和血清谷-丙转氨酶，明显保护肝损伤及抗肝纤维化。
乌药：辛，温。归肺、脾、肾、膀胱经。顺气止痛，温肾散
寒。显著降低血清转氨酶，保护肝脏免受脂肪浸润。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以某些成分确定、功效明晰的天然提取物的有序配伍，组合成了有效治疗脂肪肝的中药。
本发明可以贯穿于脂肪肝治疗的全过程，标本兼治，不易复发，安全可靠，无明显毒副反应，便于患者长期坚持服用，用药多年来，患者无任何不良反应，跟踪血液检查正常。
本发明的中药组合物原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明的中药组合物治疗脂肪肝效果显著，临床实验结果显示，用本药方施治，每日一剂，水煎100-150ml，分成两份，早晚各一份服用，以一个月为一疗程，一般一个疗程见效，三个疗程可见明显改善，六个疗程功能基本痊愈。总有效率为100％。
本发明还提供了一种由上述治疗脂肪肝的中药组合物制成的口服制剂，所述口服制 剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为片剂和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗脂肪肝的中药，其特征是由下列重量份的原料药组成：瓜蒂0.5～1重量份；儿茶1.5～3重量份；穿山龙、余甘子、乌药4～8重量份；沙苑子、地骨皮9～18重量份；绞股蓝15～30重量份。
2.根据权利要求1所述的一种治疗脂肪肝的中药，其特征是由下列重量份的原料药组成：瓜蒂1重量份；儿茶3重量份；穿山龙、余甘子、乌药8重量份；沙苑子、地骨皮18重量份；绞股蓝30重量份。
3.一种治疗脂肪肝的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗脂肪肝的口服制剂，其特征是包括口服液、片剂、胶囊剂、丸剂，优选口服液和片剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464362.1A CN111529576A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗脂肪肝的中药组合物 |
| CN2020104643621 | 2020-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112370483A true CN112370483A (zh) | 2021-02-19 |
Family
ID=71969541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010464362.1A Pending CN111529576A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗脂肪肝的中药组合物 |
| CN202011563670.6A Withdrawn CN112370483A (zh) | 2020-05-28 | 2020-12-25 | 一种治疗脂肪肝的中药组合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010464362.1A Pending CN111529576A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗脂肪肝的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111529576A (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111529576A (zh) * | 2020-05-28 | 2020-08-14 | 仲崇允 | 一种治疗脂肪肝的中药组合物 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1524552A (zh) * | 2003-02-27 | 2004-09-01 | 上海方心科技研究所 | 治疗脂肪肝的中药制剂 |
| CN102210840A (zh) * | 2011-05-29 | 2011-10-12 | 刘晓娜 | 一种治疗脂肪肝的中药胶囊 |
| CN103638445A (zh) * | 2013-11-01 | 2014-03-19 | 杨杰 | 一种治疗脂肪肝的中药组合物 |
| CN105396103A (zh) * | 2015-12-09 | 2016-03-16 | 韩祎迪 | 一种快速治疗脂肪肝的制剂 |
| CN107854588A (zh) * | 2017-12-12 | 2018-03-30 | 汤阴县瑞星生物有限公司 | 一种治疗脂肪肝的中药组合物及其制备方法 |
| CN111529576A (zh) * | 2020-05-28 | 2020-08-14 | 仲崇允 | 一种治疗脂肪肝的中药组合物 |
-
2020
- 2020-05-28 CN CN202010464362.1A patent/CN111529576A/zh active Pending
- 2020-12-25 CN CN202011563670.6A patent/CN112370483A/zh not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1524552A (zh) * | 2003-02-27 | 2004-09-01 | 上海方心科技研究所 | 治疗脂肪肝的中药制剂 |
| CN102210840A (zh) * | 2011-05-29 | 2011-10-12 | 刘晓娜 | 一种治疗脂肪肝的中药胶囊 |
| CN103638445A (zh) * | 2013-11-01 | 2014-03-19 | 杨杰 | 一种治疗脂肪肝的中药组合物 |
| CN105396103A (zh) * | 2015-12-09 | 2016-03-16 | 韩祎迪 | 一种快速治疗脂肪肝的制剂 |
| CN107854588A (zh) * | 2017-12-12 | 2018-03-30 | 汤阴县瑞星生物有限公司 | 一种治疗脂肪肝的中药组合物及其制备方法 |
| CN111529576A (zh) * | 2020-05-28 | 2020-08-14 | 仲崇允 | 一种治疗脂肪肝的中药组合物 |
Non-Patent Citations (1)
| Title |
|---|
| 蔡永敏 等: "最新中药药理与临床应用", vol. 1, 河北科学技术出版社, pages: 185 - 188 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111529576A (zh) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102579708B (zh) | 一种壮阳补肾健肝肺的中药 | |
| CN103877247B (zh) | 用于治疗褥疮的药物及其制备方法 | |
| CN112370483A (zh) | 一种治疗脂肪肝的中药组合物 | |
| CN111529579A (zh) | 一种醒酒、治疗酒精肝的中药组合物 | |
| CN102698185B (zh) | 一种治疗高血脂症的藏药及其制备方法 | |
| CN105456624A (zh) | 一种用于产后康复的中药护理组合物及其制备方法 | |
| CN111643561A (zh) | 一种治疗月经不调、痛经、闭经的中药组合物 | |
| CN100488526C (zh) | 仙硼疗氟口服制剂 | |
| CN105250417A (zh) | 一种治疗腹泻型肠易激综合征的药物组合物及其应用 | |
| CN101797291A (zh) | 治疗骨质增生的中药药物 | |
| CN1109777A (zh) | 降脂脱醇食用调料 | |
| CN106237186B (zh) | 一种治疗肺结核的中药 | |
| CN105288095A (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
| CN105362944A (zh) | 一种治疗骨科扭挫伤的中药膏剂 | |
| CN113304227A (zh) | 一种治疗神经衰弱、失眠的中药组合物 | |
| CN112439041A (zh) | 一种治疗中毒性肝炎的中药组合物 | |
| CN112426464A (zh) | 一种治疗中暑的中药组合物 | |
| CN1194847A (zh) | 脱痔膏 | |
| CN117244028A (zh) | 一种用于酒精性肝病的组合物及其制备方法和用途 | |
| CN111759900A (zh) | 一种治疗子宫脱垂的中药组合物 | |
| CN117752749A (zh) | 一种黄蜀葵复方痛风中药及其制备方法 | |
| CN113144056A (zh) | 一种提高智力的中药组合物 | |
| CN118078891A (zh) | 一种治疗气滞血瘀型ⅲ型前列腺炎的中药组合物及其制备方法 | |
| CN111714601A (zh) | 一种治疗真菌感染的中药组合物 | |
| CN111956724A (zh) | 一种治疗糖尿病的中药制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210219 |
|
| WW01 | Invention patent application withdrawn after publication |